Anatara Lifesciences Limited Stock Market Press Releases and Company Profile

Sydney, Dec 13, 2019 AEST (ABN Newswire) - Anatara Lifesciences Ltd (googlechartASX:ANR) CEO Steve Lydeamore presented to investors at the Pitt Street Research Life Sciences Conference in Sydney last month. During his presentation, Steve spoke to the Anatara story and the exciting year we have ahead with upcoming corporate milestones on both our human and animal health product opportunities.

Anatara is currently evaluating a range of evidence-based gastrointestinal consumer health products with a view to expand its current pipeline through in-licencing and distribution. In parallel, the Company continues to remain on-track to announce its human clinical trial protocol and the latest results from its preclinical animal studies for its Gastrointestinal ReProgramming dietary supplement for gut health, bringing the Company closer to partnering in 2020.

The Company remains focused on building a pipeline of evidence-based human gastrointestinal health products which will provide real outcomes for patients and drive value for its shareholders.

To view the video, please visit:

About Anatara Lifesciences Limited

Anatara Lifesciences ASX ANRAnatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. 


Investor and Media inquiries

Steven Lydeamore
Chief Executive Officer
Anatara Lifesciences Ltd
T: +61-438-027-172

Sue MacLeman
Anatara Lifesciences Ltd
T: +61-437-211-200

ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 20) (Last 30 Days: 106) (Since Published: 14072)